Phase 3 N=57 Treating Brain Swelling in Pediatric Cerebral Malaria
Malaria, Cerebral
Primary: Number of Participants Who Died — 5; 5; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=535 RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects
Gestational Diabetes
Primary: Primary Composite Outcome — 150; 167 Participants — p=0.13
Phase 3 N=513 A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
Chronic Hand Eczema
Primary: Change in HECSI Score From Baseline to Week 12 — -67.6; -51.5 score on a scale — p=<0.001
Phase 3 N=12 Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Mean Intravenous Glucose Infusion Rate — 4.33; 9.51 mg/kg/minute — p=0.0037
Phase 3 N=1,002 Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
Latent Tuberculosis Infection
Primary: Treatment Completion Rate. — 294; 248; 250 Participants
Phase 3 N=1,107 Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
Gastroesophageal Reflux Disease · Dyspepsia
Primary: Change From Baseline in Reflux Disease Questionnaire (RDQ) Scores for the GERD Dimension — -1.27; -1.06 score on a scale — p=<0.0001
Phase 3 N=430 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Change From Baseline in Mean Dysphagia Days (DD) at Week 24 — -6.85; -4.98 days — p=0.0005
Phase 3 N=96 A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Primary: Percent Change in LDL-C From Baseline to Week 12 — -25.25; -3.46 Percent Change — p=0.001
Phase 3 N=131 A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6…
Phase 3 N=400 Low Doses of Aspirin in the Prevention of Preeclampsia
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
Phase 3 N=329 Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
Gastroenteritis
Primary: Immune Response to the Licensed Pediatric DTaP-Hib-IPV-HepB Vaccine Co-administered With a 2-dose Regimen of HIL-214 at 4 and 6 Months of Age, Compared to That of the…
Phase 3 N=19 A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents
Migraine Disorders
Primary: Assessment of Recruitment Rate — 1.1; 0.6 participants per month
Phase 3 N=499 PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Huntington Disease
Primary: Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) — -1.18; -0.95 score on a scale — p=0.1670
Phase 3 N=190 Study of Diagnostic Performance of [18F]CTT1057 in BCR
Prostatic Neoplasms · Prostate Cancer · Recurrence
Primary: Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F) — 75.0; 68.9; 65.2 Percentage of regions
Phase 3 N=171 A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 — 0.39; -0.37 Percent (%) of HbA1c — p== 0.002